Al­most a year since Hu­mi­ra biosim­i­lars launched, Ab­b­Vie still con­trols more than 97% of the US mar­ket

Ab­b­Vie isn’t los­ing its con­trol of its biggest cash cow Hu­mi­ra (adal­i­mum­ab) quite yet, de­spite the in­flux of eight adal­i­mum­ab biosim­i­lars vy­ing for mar­ket share, ac­cord­ing to a new re­port from Sam­sung Bioepis.

The quar­ter­ly biosim­i­lar mar­ket re­port, re­leased Tues­day, found that de­spite the launch of eight dif­fer­ent Hu­mi­ra com­peti­tors, at var­i­ous price points from 5% dis­counts on the brand name prod­uct to 86% dis­counts (as in the case of Co­herus’ Yusim­ry), on­ly Am­gen’s Am­je­vi­ta has been able to muster 2.6% up­take.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER